CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

August 21, 2019 admin Healthcare, Investor Presentations Comments Off on CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

CytoDyn, Inc. (OTC: CYDY)

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Next Super Stock investor conference presentation 8/15/2019




Related Articles

Newsmakers

CytoDyn (OTC: CYDY) Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers

February 6, 2020 admin Newsmakers Comments Off on CytoDyn (OTC: CYDY) Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers

VANCOUVER, Washington, Feb. 06, 2020– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it […]

Healthcare

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

March 27, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020  — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]